LAMEA Castrate-Resistant Prostate Cancer Market By Therapy (Hormonal Therapy, Immunotherapy, Chemotherapy and Radiotherapy), By Country, Industry Analysis and Forecast, 2020 - 2026
Special Offering: Industry Insights | Market Trends | Highest number of Tables | 24/7 Analyst Support
Get in-depth analysis of the COVID-19 impact on the LAMEA Castrate-Resistant Prostate Cancer Market
The Latin America, Middle East and Africa Castrate-resistant Prostate Cancer Market would witness market growth of 9.1% CAGR during the forecast period (2020-2026). The increasing prevalence of castrate-resistant prostate cancer, rising adoption of novel drugs, coupled with an unhealthy lifestyle are the main factors predicted to boost the market growth. The requirement for fast treatment alternatives and funding in R&D by leading companies will also contribute to the growth of the market.
Prostate cancer is a type of cancer that develops into male reproductive systems. Generally, prostate cancer is slow-growing and stable but it may spread from the prostate (gland) to different part of the body like bone and lymph node. In the beginning, prostate cancer does not show any kind of symptom but in some serious cases, it causes pain during urination and can even cause a problem during sexual intercourse. Castration-resistant prostate cancer referred to prostate cancer that reached other body parts and resists medical or surgical treatment.
The primary factors boosting the development of the market are increasing geriatric population who are more vulnerable to castrate resistant prostate cancer, introduction of new drugs, existence of many authorized drugs and the proliferation of the product. Additionally, the increasing development of innovative drugs to manage unmet needs and existing treatment alternatives is also anticipated to fuel the growth of the market for castrate-resistant prostate cancer.
Moreover, rising research and development initiatives combined with growing prevalence of castrate resistant prostate cancer because of aging population is anticipated to boost the market growth. Further, presence of supportive reimbursement norms for patients is anticipated to fuel the growth of the market for castrate-resistant prostate cancer during the forecast period.
Based on Therapy, the market is segmented into Hormonal Therapy, Immunotherapy, Chemotherapy and Radiotherapy. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Sanofi S.A., Johnson and Johnson, Pfizer, Inc., Bayer AG, Abbott Laboratories, GlaxoSmithKline PLC (GSK), Northwest Biotherapeutics, Inc., Active Biotech AB, Astellas Pharma, Inc. and Dendreon Pharmaceuticals LLC (Sanpower Group Co., Ltd.)
Scope of the Study
Market Segments Covered in the Report:
- Hormonal Therapy
- Saudi Arabia
- South Africa
- Rest of LAMEA
- Sanofi S.A.
- Johnson and Johnson
- Pfizer, Inc.
- Bayer AG
- Abbott Laboratories
- GlaxoSmithKline PLC (GSK)
- Northwest Biotherapeutics, Inc.
- Active Biotech AB
- Astellas Pharma, Inc.
- Dendreon Pharmaceuticals LLC (Sanpower Group Co., Ltd.)
Unique Offerings from KBV Research
- Exhaustive coverage
- The highest number of market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free